Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455023 | 1.00 | REN (0.47) | RENCYP3A4 | |
| SCHEMBL5653443 | 0.91 | REN (0.49) | RENCYP3A4 | |
| SCHEMBL5653447 | 0.91 | REN (0.49) | RENCYP3A4 | |
| SCHEMBL5455037 | 0.86 | REN (0.35) | RENCYP3A4 | |
| SCHEMBL4785966 | 0.82 | REN (0.63) | RENCYP3A4 | |
| SCHEMBL4785962 | 0.82 | REN (0.63) | RENCYP3A4 | |
| SCHEMBL4785977 | 0.82 | REN (0.63) | RENCYP3A4 | |
| SCHEMBL5470620 | 0.79 | REN (0.52) | RENCYP3A4 | |
| SCHEMBL5470628 | 0.79 | REN (0.52) | RENCYP3A4 | |
| SCHEMBL5470619 | 0.79 | REN (0.52) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135405-A1 | Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-06-14 | — | — | US | disclosed |
| EP-1680427-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040173-A1 | DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135405-A1 | Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain | REN, ACE, ACE2 | REN 1/4885CYP3A4 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.